Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Free Report) was the recipient of a significant decline in short interest in September. As of September 15th, there was short interest totalling 5,200 shares, a decline of 13.3% from the August 31st total of 6,000 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 30,200 shares, the short-interest ratio is currently 0.2 days.
Hedge Funds Weigh In On Kiora Pharmaceuticals
An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC bought a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The firm bought 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals accounts for 0.8% of Stonepine Capital Management LLC’s holdings, making the stock its 16th biggest position. Stonepine Capital Management LLC owned 6.86% of Kiora Pharmaceuticals as of its most recent filing with the SEC. 76.97% of the stock is currently owned by institutional investors.
Kiora Pharmaceuticals Stock Performance
KPRX opened at $3.43 on Friday. Kiora Pharmaceuticals has a 12 month low of $3.00 and a 12 month high of $8.98. The business has a 50-day moving average of $3.78 and a two-hundred day moving average of $4.67.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on KPRX. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Kiora Pharmaceuticals in a research note on Thursday, August 22nd. Maxim Group upgraded shares of Kiora Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, June 13th.
Read Our Latest Research Report on Kiora Pharmaceuticals
About Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
Featured Articles
- Five stocks we like better than Kiora Pharmaceuticals
- What Does a Stock Split Mean?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- What is the Nikkei 225 index?
- MarketBeat Week in Review – 9/23 – 9/27
- The How and Why of Investing in Gold Stocks
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.